Thierry Conroy, MD | Authors


An Overview of a Practice-Changing Trial With mFOLFIRINOX in Pancreatic Cancer

September 05, 2018

Thierry Conroy, MD, a medical oncologist and director at the Institut de Cancerologie de Lorraine in Nancy, France, shares some background on the PRODIGE 24/CCTG PA.6 trial where a modified FOLFIRINOX regimen was found superior to the adjuvant standard of care, gemcitabine, in patients with resected pancreatic cancer.